Latest United States Startup Funding Rounds
Startup funding in United States: recent rounds, the companies behind them and their participating investors.
- Rounds
- 2,242 Jan 1 – Oct 29, 2026
- Disclosed funding
- $257.7B 1862 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| PP Develops Voice AI for quick-service restaurant drive-thrus | $10M | Undisclosed | Foodtech | United States | Investors | |
| VE Valinor EnterprisesCompany profile Builds and buys critical defense and government technology solutions Builds and buys critical defense and government technology solutions | $54M | Series A | Defense tech | United States | Investors | |
| SA Spangle AICompany profile Builds agentic infrastructure layer connecting AI-led discovery to real-time conversion for commerce Builds agentic infrastructure layer connecting AI-led discovery to real-time conversion for commerce | $15M | Series A | AI | United States | Investors | |
| ED Enhanced Digital Group Inc.Company profile Provides derivatives solutions in the digital asset space for institutional clients Provides derivatives solutions in the digital asset space for institutional clients | Undisclosed | Series A | Fintech | United States | Investors | |
| V Builds technologies for spatial biology and multi-omics innovation | $48M | Series A | Biotech | United States | Investors | |
| F Medical imaging data management and analysis platform | $27.5M | Undisclosed | Healthtech | United States | Investors | |
 EpiBiologicsCompany profile Develops bispecific antibodies for targeted degradation of extracellular proteins. Develops bispecific antibodies for targeted degradation of extracellular proteins. | $107M | Series B | Biotech | United States | Investors | |
| PM Parabilis MedicinesCompany profile Develops medicines targeting historically undruggable protein targets in cancer Develops medicines targeting historically undruggable protein targets in cancer | $305M | Series FSeries C+ | Biotech | United States | Investors Alderline GroupARCH Venture Partners +21Catalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners | |
| A Develops specialized AI systems for regulated industries | $70M | Series B | AI | United States | Investors | |
 Nocion TherapeuticsCompany profile Nocion Therapeutics develops small-molecule therapies for conditions involving cough and itch. Nocion Therapeutics develops small-molecule therapies for conditions involving cough and itch. | $23M | Series B+Series B | Biotech | United States | Investors Undisclosed |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1Y Combinator (YC)
Vera Health, BioStack, Tractian
133rounds3led - 2Andreessen Horowitz (a16z)
Hex, ASI, Eka Robotics
100rounds20led - 3General Catalyst
Hyperbolic, Re:Build, Provision Labs
73rounds8led - 4Alumni Ventures
Maxinsights, Daytona, Chariot Claims
59rounds0led - 5Sequoia Capital
Hex, Warhound, Whop
58rounds9led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.